GlassScriptPhysician profile
Lin W Chou
NPI 1083705560
$1,983.52
in general payments reported to CMS, 2019-2025
10 companies · $51.62 in 2025
The $51.62 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $434 · 2020: $243 · 2021: $291 · 2022: $223 · 2023: $524 · 2024: $217 · 2025: $51.62.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $793.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $792.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $689.46 | 2019-2024 | Wegovy, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $646.20 | 2019-2025 | Farxiga, Breztri |
| Abbvie INC. | $250.20 | 2021-2024 | |
| Ibsa Pharma INC. | $160.75 | 2019-2021 | |
| Abiomed | $74.95 | 2023 | Impella |
| Glaxosmithkline, LLC. | $61.32 | 2022-2023 | Arexvy, Shingrix |
| Merck Sharp & Dohme LLC | $36.98 | 2019-2020 | |
| Daiichi Sankyo INC. | $28.10 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $21.33 | 2025 | |
| Pfizer INC. | $14.23 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lin Chou listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.